

**IN THE CLAIMS:**

This is a complete listing of the claims.

1. (Original) A pharmaceutical composition comprising one or more peptides selected from the group consisting of:
  - a) a peptide having the sequence of any of SEQ ID NO:1 to SEQ ID NO:36;
  - b) a peptide homologous to any one of SEQ ID NO:1 to SEQ ID NO:36 from another flavivirus; and
  - c) a peptide functionally equivalent to any one of SEQ ID NO:1 to SEQ ID NO:36, wherein the functionally equivalent peptide is identical to at least one of SEQ ID NO:1 to SEQ ID NO:36 except that one or more amino acid residues has been substituted with a homologous amino acid, resulting in a functionally silent change, or one or more amino acids has been deleted.
2. (Currently Amended) A pharmaceutical composition comprising at least one peptide selected from the one or more of the following:
  - a) a peptide having the amino acid sequence one or more of SEQ ID NO:1 to SEQ ID NO:36, wherein the N-terminal “Xaa” is amino acid residue comprises an N-terminal amino group and the C-terminal “Xaa” is amino acid residue comprises a c-terminal carboxyl group;
  - b) a peptide having the sequence of any of SEQ ID NO:1 to SEQ ID NO:36, wherein the chemical moiety at the peptide's N-terminus N-terminal “Xaa” is not an amino group and/or the chemical moiety at the peptide's C-terminus C-terminal “Xaa” is not a carboxyl group, wherein the N-terminal “Xaa” chemical moiety is selected from the group consisting of: an acetyl group, a hydrophobic group, carbobenzoyl group, dansyl group, a t-butyloxycarbonyl group, or a macromolecular carrier group, and/or wherein the C-terminal “Xaa” chemical moiety is selected from the group consisting of an amido group, a hydrophobic group, t-butyloxycarbonyl group or a macromolecular group;
  - c) a peptide having the sequence of any of SEQ ID NO:1 to SEQ ID NO:36, wherein at least one bond linking adjacent amino acid residues is a non-peptide bond;

- d) a peptide having the sequence of any of SEQ ID NO:1 to SEQ ID NO:36, wherein at least one amino acid residue is in the D-isomer configuration;
- e) a peptide as in part "a)" or "b)" except that at least one amino acid has been substituted for by a different amino acid; or
- f) a functional fragment of a peptide as set out in any of parts "a)" to "e)", having at least 3 contiguous nucleotides of any one of SEQ ID NO:1 to SEQ ID NO:36.

3. (Original) The composition of claim 2 wherein the peptide is selected from one or more of the group consisting of SEQ ID NO:1, 2, 3, and 4.

4. **(Currently Amended)** The composition of claim 3 wherein the N-terminal "Xaa" chemical moiety is an acetyl group, a hydrophobic group a carbobenzoyl group, a dansyl group, a t-butyloxycarbonyl group, or a macromolecular carrier group; and/or the C-terminal "Xaa" chemical moiety is a hydrophobic group, a t-butyloxycarbonyl group or a macromolecular group.

5. **(Currently Amended)** The composition of claim 3 wherein the N-terminal "Xaa" chemical moiety is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate; and/or the C-terminal "Xaa" chemical moiety is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate.

6. **(Currently Amended)** The composition of claim 3 wherein at least one bond linking adjacent amino acid residues in the peptide is a non-peptide bond selected from the group consisting of an imido bond, an ester bond, a hydrazine bond, a semicarbazide bond and an azo bond.

7. (Original) The composition of 3 wherein at least one amino acid is a D-isomer amino acid.

8. **(Currently Amended)** The composition of claim 3 wherein N-terminal "Xaa" chemical moiety is an amino group and the C-terminal "Xaa" chemical moiety is a carboxyl group.

9. (Original) The composition of claim 2 wherein the peptide is selected from one or more of the group consisting of SEQ ID NO:5, 13, 21, and 29.

10. **(Currently Amended)** The composition of claim 9 wherein the N-terminal “Xaa” chemical moiety is an acetyl group, a hydrophobic group a carbobenzoyl group, a dansyl group, a t-butyloxycarbonyl group, or a macromolecular carrier group; and/or the C-terminal “Xaa” chemical moiety is a hydrophobic group, a t-butyloxycarbonyl group or a macromolecular group.

11. **(Currently Amended)** The composition of claim 9 wherein the N-terminal “Xaa” chemical moiety is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate; and/or the C-terminal “Xaa” chemical moiety is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate.

12. **(Currently Amended)** The composition of claim 9 wherein at least one bond linking adjacent amino acid residues in the peptide is a non-peptide bond selected from the group consisting of an imido bond, an ester bond, a hydrazine bond, a semicarbazoide bond and an azo bond.

13. (Original) The composition of claim 9 wherein at least one amino acid is a D-isomer amino acid.

14. **(Currently Amended)** The composition of claim 9 wherein the N-terminal “Xaa” chemical moiety is an amino group and the C-terminal “Xaa” chemical moiety is a carboxyl group.

15. (Original) The composition of claim 2 wherein the peptide is selected from one or more of the group consisting of SEQ ID NO:6–9, 14–17, 22–25, and 30–33.

16. **(Currently Amended)** The composition of claim 15 wherein the N-terminal “Xaa” chemical moiety is an acetyl group, a hydrophobic group a carbobenzoyl group, a dansyl group, a t-butyloxycarbonyl group, or a macromolecular carrier group; and/or the C-terminal “Xaa” chemical moiety is a hydrophobic group, a t-butyloxycarbonyl group or a macromolecular group.

17. **(Currently Amended)** The composition of claim 15 wherein the N-terminal “Xaa” chemical moiety is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate; and/or the C-terminal “Xaa” chemical moiety is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate.

18. **(Currently Amended)** The composition of claim 15 wherein at least one bond linking adjacent amino acid residues in the peptide is a non-peptide bond selected from the group consisting of an imido bond, an ester bond, a hydrazine bond, a semicarbazoide bond and an azo bond.

19. (Original) The composition of claim 15 wherein at least one amino acid is a D-isomer amino acid.

20. **(Currently Amended)** The composition of claim 15 wherein the N-terminal “Xaa” chemical moiety is an amino group and the C-terminal “Xaa” chemical moiety is a carboxyl group.

21. (Original) The composition of claim 2 wherein the peptide is selected from one or more of the group consisting of SEQ ID NO:10–12, 18–20, 26–28, and 34–36.

22. **(Currently Amended)** The composition of claim 21 wherein the N-terminal “Xaa” chemical moiety is an acetyl group, a hydrophobic group a carbobenzoxyl group, a dansyl group, a t-butyloxycarbonyl group, or a macromolecular carrier group; and/or the C-terminal “Xaa” chemical moiety is a hydrophobic group, a t-butyloxycarbonyl group or a macromolecular group.

23. **(Currently Amended)** The composition of claim 21 wherein the N-terminal “Xaa” chemical moiety is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate; and/or the C-terminal “Xaa” chemical moiety is a macromolecular carrier group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate.

24. **(Currently Amended)** The composition of claim 21 wherein at least one bond linking adjacent amino acid residues in the peptide is a non-peptide bond selected from the group consisting of an imido bond, an ester bond, a hydrazine bond, a semicarbazoide bond and an azo bond.

25. (Original) The composition of claim 21 wherein at least one amino acid is a D-isomer amino acid.

26. **(Currently Amended)** The composition of claim 21 wherein the N-terminal “Xaa” chemical moiety is an amino group and the C-terminal “Xaa” chemical moiety is a carboxyl group.
27. (Original) A method of treating or preventing a Flavivirus infection comprising administering to the patient an effective amount of a pharmaceutical composition according to claim 1.
28. (Original) A method of treating or preventing a Flavivirus infection comprising administering to the patient an effective amount of a pharmaceutical composition according to claim 2.
29. (Original) A substantially purified antibody specific for a peptide as described in claim 1.
30. **(Currently amended)** A substantially purified antibody specific for a peptide as described in claim 2 claim 0.

**IN THE SPECIFICATION:**

I. Please amend paragraphs [0001] and [0010] as follows:

[0001] This application Application claims Benefit of United States Provisional Application serial number 60/424,746, filed November 8, 2002 is a §371 U.S. national stage filing of international application PCT/US2003/035666, filed 7 November 2003 (published in English on 27 May 2004 as WO 2004/044220) and claiming priority to US 60/424,746 filed 8 November 2002, each of which is incorporated by reference, in its entirety.

[0010] Various aspects of this embodiment of the invention provide for compositions that comprise one or more peptides selected from the following.

- A) Peptides having the amino acid sequence one or more of SEQ ID NO:1 to SEQ ID NO:36, wherein the N-terminal “Xaa” chemical moiety (also referred to as “X”, below) is an amino group and the C-terminal “Xaa” chemical moiety (also referred to as “Z”, below) is a carboxyl group.
- B) Peptides having the sequence of any of SEQ ID NO:1 to SEQ ID NO:36, wherein the N-terminal “Xaa” chemical moiety is not an amino group and/or the C-terminal “Xaa” chemical moiety is not a carboxyl group, wherein the N-terminal “Xaa” chemical moiety is selected from the group consisting of: an acetyl group, a hydrophobic group, carbobenzoyl group, dansyl group, a t-butyloxycarbonyl group, or a macromolecular carrier group, and/or wherein the C-terminal “Xaa” chemical moiety is selected from the group consisting of an amido group, a hydrophobic group, t-butyloxycarbonyl group or a macromolecular group.
- C) Peptides having the sequence of any of SEQ ID NO:1 to SEQ ID NO:36 except that at least one bond linking adjacent amino acid residues is a non-peptide bond.
- D) Peptides having the sequence of any of SEQ ID NO:1 to SEQ ID NO:36, except that at least one amino acid residue is in the D-isomer configuration.
- E) Peptides as in groups “A)” or “B)” except that at least one amino acid has been substituted for by a different amino acid (whether a conservative or non-conservative change).

F) Peptides that are a functional fragment of a peptide as set out in any of groups "A)" to "E)", above, where the peptides have at least 3 contiguous nucleotides of any one of SEQ ID NO:1 to SEQ ID NO:36.

**II.** Please replace the original sequence listing with the substitute sequence listing submitted herewith.